Pfizer to sell Chinese biologics manufacturing facility to WuXi
Multinational makes ‘difficult decision’ to halt presence in Chinese biosimilars market five years after $350 million investment
Pfizer has agreed to sell its single-use biologics manufacturing plant in Hangzhou, eastern China to Chinese contract development and manufacturing organisation, WuXi Biologics, five years after investing $350 million to build the facility.
The sale of the 50,000 sq m facility, which has been operational since 2018, effectively ends Pfizer’s involvement in the Chinese biosimilars market. Pfizer had originally planned to manufacture three biosimilars for the Chinese market.
The transaction is expected to close in the first half of 2021 and financial details have not been disclosed.
“After a comprehensive review of the biosimilars market and the company’s global manufacturing network, Pfizer has made a difficult decision to halt its biosimilars programs in China and to sell 100% of its equity interest in Pfizer Biologics (Hangzhou) Co. Ltd,” Pfizer said in a statement sent to CPHI Online.
“This transaction notwithstanding, Pfizer remains committed to continue to realize its purpose – breakthroughs that change patients’ lives in China,” the company added.
In a statement, Wuxi Biologics said the addition of Hangzhou and its entire labour force would boost its drug substance and drug product capacities to “address surging manufacturing demands” and that production would start shortly after the closure of the deal.
The Hangzhou plant includes drug substance capacities equipped with two 2000L single-use bioreactors expandable to 4x2000L and drug product capacities of vial filling and pre-filled syringe.
“Globally DS and especially DP capacities are in urgent need now,” said Dr. Chris Chen, CEO of WuXi Biologics. “The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance